Fundraising Fox

ExThera Medical

Martinez, US · Delaware corporation · 2 known investors

BiotechHealthtech

Founders & leadership

MD
Michael DiMeoExecutive
EBErin Borger
Erin BorgerExecutive
RSRobert S. Ward
Robert S. WardExecutive
KM
Keith McCreaExecutive
GP
George PitarraExecutive
KW
Kathleen WhiteExecutive

Board

JP
John PrestonBoard director
JF
John FeikBoard director
JP
Jacqueline PriceBoard director
LC
Lakhmir ChawlaBoard director
EJ
Eber JaquesBoard director

Investors · 2

Cycad Group LLCSanta Barbara
Fresenius Medical Care VenturesBad Homburg

Reported raises · per SEC filings

Form D private placements

$62.8M disclosed across 6 rounds · 2012–2024

▶$1.5MraisedSep 2024 · 23 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael DiMeoExecutive Officer
  • Erin BorgerExecutive Officer, Director
  • Jacqueline PriceDirector
  • John PrestonDirector
  • Robert S. WardExecutive Officer, Director
  • Lakhmir ChawlaDirector
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedSep 2021 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert S. WardExecutive Officer, Director
  • Lakhmir ChawlaDirector
  • Michael BenjaminExecutive Officer
  • Greg DollarhydeDirector
  • Erin BorgerDirector
  • John PrestonDirector
Offering amount
$20M
Amount sold
$6.7M
First sale
Jul 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.6MraisedMar 2021 · 66 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert S. WardExecutive Officer, Director
  • John PrestonDirector
  • Lakhmir ChawlaExecutive Officer, Director
  • Michael PorterDirector
  • Greg DollarhydeDirector
Offering amount
$20.6M
Amount sold
$20.6M
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedMay 2016 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathleen WhiteExecutive Officer
  • John FeikDirector
  • George PitarraExecutive Officer, Director
  • Eber JaquesDirector
  • Robert WardExecutive Officer, Director
  • Keith McCreaExecutive Officer, Director
Offering amount
$7M
Amount sold
$6.7M
Minimum investment
$20K
First sale
Sep 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.3MraisedMay 2016 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith McCreaExecutive Officer, Director
  • Eber JaquesDirector
  • George PitarraExecutive Officer, Director
  • Robert WardExecutive Officer, Director
  • Kathleen WhiteExecutive Officer
  • John FeikDirector
Offering amount
$15.4M
Amount sold
$15.3M
First sale
Apr 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedMay 2016 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith McCreaExecutive Officer, Director
  • Kathleen WhiteExecutive Officer
  • George PitarraExecutive Officer, Director
  • Robert WardExecutive Officer, Director
  • John FeikDirector
  • Eber JaquesDirector
Offering amount
$12.5M
Amount sold
$12M
First sale
Apr 2012
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
AltaThera Pharmaceuticals14 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
SonoThera13 shared keywordsSonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.
RayThera13 shared keywordsRayThera develops small molecule therapies targeting unmet needs in immunology. The company focuses on drug discovery in the biotechnology and immunology space.
Carthera10 shared keywordsCarthera develops the SonoCloud implantable device, which uses low intensity pulsed ultrasound and infused gas microbubbles to temporarily and reversibly open the blood-brain barrier. The technology aims to improve delivery of chemotherapies, immunotherapies, and other agents to the brain for treating brain cancers such as gliomas and other brain diseases.

Companies competing with ExThera Medical for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

ExThera Medical Announces Resolution of Federal Investigation | Press Releases | napavalleyregister.comnapavalleyregister.com · Mar 2026District of Massachusetts | Chief Regulatory Officer for ExThera Medical Charged with Concealing Adverse Events, Including Deaths, from FDA; ExThera Medical Corporation Resolves Investigation | United States Department of Justicejustice.gov · Mar 2026Investors | ExTheraextheramedical.com

Frequently asked questions

Who are ExThera Medical's investors?
ExThera Medical's investors include Cycad Group LLC, Fresenius Medical Care Ventures.
How much funding has ExThera Medical raised?
ExThera Medical has disclosed $62.8M raised across 6 rounds.
Where is ExThera Medical headquartered?
ExThera Medical is headquartered in Martinez, US.